Upadacitinib (Rinvoq®) for the treatment of chronic severe atopic dermatitis (AD) - 25 May 2021
Allergy & Anaphylaxis Australia to made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme listing of Upadacitinib (Rinvoq®) for the treatment of chronic severe atopic dermatitis (AD).
A&AA Upadacitinib Rinvoq Submission May 2021183.25 KB